[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl]

Naohiro Sekiguchi; Naoki Takezako; Mitsuhiro Haga; Akihisa Nagata; Satoshi Noto; Akiyoshi Miwa

[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl]

Rinsho Ketsueki. 2011 Feb;52(2):87-9.

[Article in Japanese]

Authors

Naohiro Sekiguchi¹, Naoki Takezako, Mitsuhiro Haga, Akihisa Nagata, Satoshi Noto, Akiyoshi Miwa

Affiliation

¹ Division of Hematology, National Hospital Organization Disaster Medical Center.

PMID: 21403430

Abstract

Here, we retrospectively assessed the reversibility of renal impairment and anti-myeloma effect of bortezomib and dexamethasone (BD therapy) for Japanese patients with multiple myeloma showing a serum creatinine level above 2 mg/dl. Improvement of renal impairment was observed in 6 of 7 patients following a median of 2.4 cycles of BD therapy. Three of 7 patients achieved more than partial response by BD therapy. The present study demonstrated that BD therapy was highly effective for the treatment of Japanese myeloma patients with renal impairment.

Publication types

English Abstract

MeSH terms

Aged
Biomarkers / blood
Boronic Acids / administration & dosage*
Bortezomib
Creatinine / blood*
Dexamethasone / administration & dosage*
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Kidney Diseases / drug therapy*
Kidney Diseases / etiology
Male
Middle Aged
Multiple Myeloma / complications
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Pyrazines / administration & dosage*
Retrospective Studies
Treatment Outcome

Substances

Biomarkers
Boronic Acids
Pyrazines
Bortezomib
Dexamethasone
Creatinine